C-145-03

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145-03) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

NOW RECRUITING: Iovance is conducting a Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145-03) followed by IL-2 in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.

Key eligibility criteria:
• Measurable metastatic disease and ≥ 1 lesion resectable for TIL generation
• At least one prior systemic therapy
• Age ≥ 18
• ECOG PS 0-1

Endpoints: Safety and Efficacy

Physicians

To learn more about the trial on ClinicalTrials.gov, including eligibility criteria, locations and contacts, please click here:

Identifier: NCT03083873

Clinical.Inquiries@iovance.com
1-866-565-4410

Patients

If you have been diagnosed with recurrent and/or metastatic Squamous Cell Carcinoma, have previously undergone at least one systemic treatment, and are interested in participating in this trial, please talk to your doctor.

If you have other questions or would like more information on this trial:

CLINICALTRIALS.GOV